112 results
10-Q
2024 Q2
Inhibrx Biosciences, Inc.
13 Aug 24
Quarterly report
4:03pm
Depreciation and amortization expense for the three and six months ended June 30, 2024 and June 30, 2023 consisted of the following (in thousands):
THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | |||||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
Research and development | $ | 374 | $ | 242 | $ | 631 | $ | 479 | General and administrative | 101 | 53 | 205 | 110 | Total depreciation and amortization expense | $ | 475 | $ | 295 | $ | 836 | $ | 589 |
10-Q
2024 Q2
Inhibrx Biosciences, Inc.
13 Aug 24
Quarterly report
4:03pm
SIX MONTHS ENDED JUNE 30, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash flows from operating activities | Net income (loss) | $ | 1,779,301 | $ | (95,968) | Adjustments to reconcile net income (loss) to net cash used in operating activities: | Depreciation and amortization | 836 | 589 | Accretion of debt discount and non-cash interest expense | 2,065 | 2,413 | Stock-based compensation expense | 52,571 | 11,889 | Non-cash lease expense | 941 | 864 | Loss on disposal of fixed assets | — | 2 | Non-cash gain on transaction with Acquirer | (1,998,809) | — | Changes in operating assets and liabilities: | Accounts receivable | (100) | (84) | Other receivables | (345) | — | Receivables from related parties | (164) | 14 | Prepaid expenses and other current assets | (3,446) | (4,131) | Other non-current assets | (3,581) | — | Accounts payable | 21,472 | 792 | Accrued expenses | 29,853 | 2,327 | Operating lease liability | (1,002) | (903) | Deferred revenue, current portion | — | (47) | Net cash used in operating activities | (120,408) | (82,243) | Cash flows from investing activities | Purchase of fixed assets | (2,334) | (340) | Net cash used in investing activities | (2,334) | (340) | Cash flows from financing activities | Proceeds from the exercise of stock options | 71,678 | 1,210 | Net cash provided by financing activities | 71,678 | 1,210 | Net decrease in cash and cash equivalents | (51,064) | (81,373) | Cash and cash equivalents at beginning of period | 277,924 | 273,865 | Cash and cash equivalents at end of period | $ | 226,860 | $ | 192,492 | Supplemental schedule of non-cash investing and financing activities | Payable for purchase of fixed assets | $ | 207 | $ | 582 | |||||||||||||||||||||||||||||||||||||
10-Q
2024 Q2
Inhibrx Biosciences, Inc.
13 Aug 24
Quarterly report
4:03pm
In periods in which the Company has a net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):
THREE MONTHS ENDED JUNE 30, 2024 | SIX MONTHS ENDED JUNE 30, 2024 | Outstanding stock options | 187 | 365 | Warrants to purchase common stock | 1 | 1 | Total | 188 | 366 |
10-Q
2024 Q2
Inhibrx Biosciences, Inc.
13 Aug 24
Quarterly report
4:03pm
Stock-based compensation expense for stock options under the 2017 Plan consisted of the following (in thousands):
THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | |||||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
Research and development | $ | 28,617 | $ | 4,245 | $ | 32,809 | $ | 8,094 | General and administrative | 16,520 | 2,008 | 18,725 | 3,795 | Total stock-based compensation expense | $ | 45,137 | $ | 6,253 | $ | 51,534 | $ | 11,889 |
10-Q
2024 Q2
Inhibrx Biosciences, Inc.
13 Aug 24
Quarterly report
4:03pm
The operating right-of-use asset and operating lease liability as of June 30, 2024 and December 31, 2023 were as follows (in thousands):
AS OF | AS OF | ||||||||||||||||||||||||
JUNE 30, 2024 | DECEMBER 31, 2023 | ||||||||||||||||||||||||
Operating right-of-use asset | $ | 2,011 | $ | 2,952 | Operating lease liability | Current | $ | 2,171 | $ | 2,063 | Non-current | — | $ | 1,110 | Total operating lease liability | $ | 2,171 | $ | 3,173 |
10-Q
ysivn3 6w
13 Aug 24
Quarterly report
4:03pm
10-Q
kuas83q 4m3l6t8yqe
13 Aug 24
Quarterly report
4:03pm
10-Q
cu1d0c
13 Aug 24
Quarterly report
4:03pm
10-Q
z5dfwl
13 Aug 24
Quarterly report
4:03pm
10-Q
hdxoprqz9f
13 Aug 24
Quarterly report
4:03pm
10-Q
l06jn2jc
13 Aug 24
Quarterly report
4:03pm
10-Q
qzx9ijeys6xbbv0t1r9
13 Aug 24
Quarterly report
4:03pm
10-Q
w5lrfg6k4aw c1
13 Aug 24
Quarterly report
4:03pm
10-Q
jqdw5hai3bntt8
13 Aug 24
Quarterly report
4:03pm
10-Q
m7b578cmvaw1
13 Aug 24
Quarterly report
4:03pm
10-Q
6dwn8a4
13 Aug 24
Quarterly report
4:03pm
10-Q
n2kny0lkmba lwd2nx0
13 Aug 24
Quarterly report
4:03pm
10-Q
wdvm0n1ntxtmop
13 Aug 24
Quarterly report
4:03pm
10-Q
ifiy064j5
13 Aug 24
Quarterly report
4:03pm
10-Q
xuhz74y7uqh
13 Aug 24
Quarterly report
4:03pm